You just read:

Ocera Therapeutics receives CE Mark for Zysa™ for the treatment of diarrhea-predominant Irritable Bowel Syndrome (IBS-d)

News provided by

Ocera Therapeutics, Inc.

May 18, 2012, 08:00 ET